ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.

NCT00040625 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS

Last updated 2007-03-15

No results posted yet for this study

Summary

This study is to evaluate the effects (good and bad) of ALIMTA and Cisplatin or ALIMTA alone on you and your malignant pleural mesothelioma as well as make ALIMTA available to patients who qualify for treatment.

Conditions

Interventions

DRUG

Pemetrexed

DRUG

Cisplatin

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States
  • Brazil
  • Egypt
  • Saudi Arabia

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00040625 on ClinicalTrials.gov